Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 6/2020

Inhalt (21 Artikel)

Advances and perspectives of dendritic cell-based active immunotherapies in follicular lymphoma

  • Review

Maria Christina Cox, Caterina Lapenta, Stefano M. Santini

Development and characterization of a novel anti-OX40 antibody for potent immune activation

  • Original Article

Zhihui Kuang, Hua Jing, Zhihai Wu, Jie Wang, Yiming Li, Haiqing Ni, Pan Zhang, Weiwei Wu, Min Wu, Shuaixiang Zhou, Xuan Qiu, Dongdong Wu, Bianka Prinz, Hemanta Baruah, Bingliang Chen, Michael Yu, Junjian Liu

miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy

  • Original Article

Meng Zhang, Yanmei Shi, Yujuan Zhang, Yifan Wang, Faizah Alotaibi, Li Qiu, Hongmei Wang, Shanshan Peng, Yanling Liu, Qing Li, Dian Gao, Zhigang Wang, Keng Yuan, Fang-fang Dou, James Koropatnick, Jianping Xiong, Weiping Min

CD1d expression and invariant natural killer T-cell numbers are reduced in patients with upper gastrointestinal cancers and are further impaired by commonly used chemotherapies

  • Original Article

Ashanty M. Melo, Melissa J. Conroy, Emma K. Foley, Éilis Dockry, Eamon P. Breen, John V. Reynolds, Joanne Lysaght, Derek G. Doherty

Nivolumab in patients with metastatic renal cell carcinoma and chronic hepatitis C virus infection

  • Original Article

Ilya Tsimafeyeu, Rustem Gafanov, Svetlana Protsenko, Anna Semenova, Ani Oganesyan, Nurzhan Nurgaliyev, Sergei Krasny, Anastasia Bondarenko, Sufia Safina, Kristina Zakurdaeva

Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer

  • Original Article

Mizuho Ohara, Kenzo Ohara, Takumi Kumai, Takayuki Ohkuri, Toshihiro Nagato, Yui Hirata-Nozaki, Akemi Kosaka, Marino Nagata, Ryusuke Hayashi, Shohei Harabuchi, Yuki Yajima, Kensuke Oikawa, Yasuaki Harabuchi, Yasuo Sumi, Hiroyuki Furukawa, Hiroya Kobayashi

Critical role of PD-L1 expression on non-tumor cells rather than on tumor cells for effective anti-PD-L1 immunotherapy in a transplantable mouse hematopoietic tumor model

  • Original Article

Jose-Ignacio Rodriguez-Barbosa, Miyuki Azuma, Gennadiy Zelinskyy, Jose-Antonio Perez-Simon, Maria-Luisa del Rio

Oncolytic Newcastle disease virus activation of the innate immune response and priming of antitumor adaptive responses in vitro

  • Open Access
  • Original Article

Shannon Burke, Amy Shergold, Matthew J. Elder, Justine Whitworth, Xing Cheng, Hong Jin, Robert W. Wilkinson, James Harper, Danielle K. Carroll

Prostaglandin E2 in a TLR3- and 7/8-agonist-based DC maturation cocktail generates mature, cytokine-producing, migratory DCs but impairs antigen cross-presentation to CD8+ T cells

  • Open Access
  • Original Article

Philipp Gierlich, Veronika Lex, Antje Technau, Anne Keupp, Lorenz Morper, Amelie Glunz, Hanno Sennholz, Johannes Rachor, Sascha Sauer, Ana Marcu, Götz Ulrich Grigoleit, Matthias Wölfl, Paul G. Schlegel, Matthias Eyrich

Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival

  • Open Access
  • Original Article

Karl-Frederick Karstens, Jan Kempski, Anastasios D. Giannou, Penelope Pelczar, Babett Steglich, Stefan Steurer, Eric Freiwald, Anna Woestemeier, Leonie Konczalla, Michael Tachezy, Matthias Reeh, Maximilian Bockhorn, Daniel Perez, Oliver Mann, Ansgar W. Lohse, Thomas Roesch, Jakob R. Izbicki, Nicola Gagliani, Samuel Huber

Identification and validation of tumour microenvironment-based immune molecular subgroups for gastric cancer: immunotherapeutic implications

  • Original Article

Yu-Jie Zhou, Gui-Qi Zhu, Xiao-Fan Lu, Kenneth I. Zheng, Qi-Wen Wang, Jin-Nan Chen, Qing-Wei Zhang, Fang-Rong Yan, Xiao-Bo Li

Myeloid-derived suppressor cells impede T cell functionality and promote Th17 differentiation in oral squamous cell carcinoma

  • Original Article

Asif A. Dar, Rushikesh S. Patil, Trupti N. Pradhan, Devendra A. Chaukar, Anil K. D’Cruz, Shubhada V. Chiplunkar

Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma

  • Original Article

Lata Singh, Mithalesh Kumar Singh, Moshahid Alam Rizvi, Sameer Bakhshi, Rachna Meel, Neiwete Lomi, Seema Sen, Seema Kashyap

Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy

  • Open Access
  • Original Article

Malgorzata Wachowska, Joanna Stachura, Katarzyna Tonecka, Klaudyna Fidyt, Agata Braniewska, Zuzanna Sas, Iwona Kotula, Tomasz Piotr Rygiel, Louis Boon, Jakub Golab, Angelika Muchowicz

Neutrophils are mediators of metastatic prostate cancer progression in bone

  • Open Access
  • Original Article

Diane L. Costanzo-Garvey, Tyler Keeley, Adam J. Case, Gabrielle F. Watson, Massar Alsamraae, Yangsheng Yu, Kaihong Su, Cortney E. Heim, Tammy Kielian, Colm Morrissey, Jeremy S. Frieling, Leah M. Cook

Intratumoral injection of hemagglutinating virus of Japan-envelope vector yielded an antitumor effect for advanced melanoma: a phase I/IIa clinical study

  • Clinical Trial Report

Eiji Kiyohara, Atsushi Tanemura, Megumi Nishioka, Mizuho Yamada, Aya Tanaka, Akinori Yokomi, Atsuhiro Saito, Kazuma Sakura, Toshihiro Nakajima, Akira Myoui, Toshiharu Sakurai, Yutaka Kawakami, Yasufumi Kaneda, Ichiro Katayama

Cancer bio-immunotherapy XVI annual NIBIT-(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy

  • Meeting Report

Matteo Bellone, Arianna Brevi, Stefania Bruzzì, Michela Consonni, Francesca De Santis, Giulia Di Lullo, Maria Teresa Majorini, Anna Pastò, Alberto Amadori, Marco Bregni, Massimo Di Nicola, Luana Calabrò, Pier Francesco Ferrucci, Enrico Proietti, Mario Paolo Colombo, Vincenzo Russo

Neu im Fachgebiet Onkologie

Vorteile für TFOX bei HER2-negativem Magenkrebs

TFOX – ein modifiziertes FLOT-Schema – ist bei fortgeschrittenem HER2-negativem Magenkrebs offenbar wirksamer als FOLFOX: Sowohl das progressionsfreie Überleben als auch das Gesamtüberleben werden durch TFOX deutlich verlängert. Jedoch profitieren nicht alle von dieser Triplet-Therapie.

Alternde Blutbildung lässt solide Tumoren wachsen

Bestimmte mutierte Blutzellen erhöhen nicht nur das Risiko für hämatologische Neoplasien, sondern sind offenbar auch bei soliden Tumoren prognostisch ungünstig. Dafür sprechen aktuelle Erkenntnisse, insbesondere beim nichtkleinzelligen Lungenkarzinom.

ctDNA erkennt minimale Resterkrankung beim Melanom

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA (ctDNA) könnte auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Höhere Dosis von Dexamethason senkt Überlebenschancen

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.